---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-036705"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:12:10.322776+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Prime Medicine reports ~$101.8M cash as of June 30; terminates ATM prospectus

## Summary
- Preliminary cash, equivalents, and short-term investments ~$101.8M at June 30, 2025; plus $13.7M restricted cash.
- Terminated ATM prospectus under S-3 effective July 30; no further sales pending new filing.
- Sales agreement with Jefferies remains in force but ATM program currently inactive.
- Updated July 2025 corporate presentation posted on company website; includes pipeline updates.
- Company expects to report complete Q2 results in Form 10-Q; estimates subject to final adjustments.

## SEC filing metadata
- accession: 0001628280-25-036705
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025036705/0001628280-25-036705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025036705/prme-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-036705
- JSON: https://secwatch.observer/filing/0001628280-25-036705.json
- Plain text: https://secwatch.observer/filing/0001628280-25-036705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.